Last updated: April 24, 2026
What is CA2869945 in the Canadian patent record?
CA2869945 is a Canadian patent publication with the title:
- “Use of indomethacin…” (publication record for CA2869945)
A precise mapping of the exact assignee, priority dates, expiry/term status, and the full claim set requires the patent document text (claims + description) from the Canadian Intellectual Property Office (CIPO) record. The CA2869945 scope and claim-by-claim boundaries cannot be reproduced accurately without the actual claim language.
What is the claim scope?
Claim scope must be derived from the issued/published claim language (method claims, use claims, product claims, dependent claim limitations, and any explicit claim construction elements). Without the CA2869945 claims text, any reconstruction would risk mis-stating:
- the intended therapeutic indication(s),
- the patient population qualifiers,
- the route/dose/timing limits,
- the combination partners (if any),
- the treatment regimen definition, and
- the mechanistic or marker-based constraints (if present).
No complete, accurate “scope” analysis can be provided without the claim set.
What does the landscape look like in Canada around indomethacin-related uses?
Indomethacin use patents in Canada typically cluster around:
- repurposed indications (use of known NSAIDs for specific diseases),
- combination therapies (indomethacin plus a co-agent),
- formulation or dosing (if claimed as distinct embodiments),
- and skin/inflammation/oncology/neurology segments depending on the underlying indication.
But a credible landscape for CA2869945 in Canada must show:
- closest prior art families that were cited at prosecution or that predate priority,
- co-existing Canadian filings that share similar claim structure,
- and whether CA2869945 overlaps with patents covering the drug substance, the dosage form, or the claimed medical use.
A full landscape requires the following items from patent databases and the CA record:
- bibliographic data (assignee, inventors),
- the exact claim text,
- prosecution history (if accessible),
- CPC/IPC classification and cited documents,
- and any related Canadian family members and continuations.
Those inputs are not available in the current context, so a litigation-grade landscape cannot be produced without inventing facts.
What competitors and overlaps should you check in Canada?
For a Canada use patent anchored on a known compound like indomethacin, the highest-probability overlap zones to analyze in freedom-to-operate and invalidity posture are:
-
Earlier “use of indomethacin” patents
- Same disease/indication
- Same patient selection
- Same route and dosing schedule
-
Earlier indomethacin combination therapy patents
- Co-administration with the same companion drug(s)
-
Earlier formulation patents
- Controlled-release or specialized delivery that creates an operational distinction
-
Later patents that attempt to narrow or reframe
- New biomarkers
- Subpopulations
- Different endpoints that recharacterize the “use”
A correct competitor mapping still depends on the actual CA2869945 claim elements.
How does the Canadian regulatory-patent linkage affect risk?
Canada’s Patent Register under the NOC/c framework can drive enforcement risk through listing of patents against a given drug product. The actionable items to determine for CA2869945 are:
- Is CA2869945 listed on the Patent Register against the relevant drug product containing indomethacin?
- Does it list as a drug substance, drug product, or medical use patent type?
- Is it subject to any court proceedings or section 8/8(1) NOC/c litigation?
None of this can be asserted without access to:
- the specific drug product(s) on the register, and
- CA2869945’s registration entries (if any).
What is the most decision-relevant “scope” conclusion?
Given only the high-level publication title and without the claim text, the only accurate statement is that CA2869945 is framed as a medical-use patent involving indomethacin (“Use of indomethacin…”). The precise scope is claim-dependent and cannot be determined from the title alone.
Key Takeaways
- CA2869945 is a Canadian medical-use patent positioned around “Use of indomethacin…”.
- A claim-by-claim scope and a defensible Canadian landscape require the actual claim language and the CIPO record text.
- Indomethacin use patents typically overlap most with earlier indication-specific use patents, combination therapy patents, and formulation/dosing patents, but the actual overlap for CA2869945 is claim-dependent.
FAQs
-
Is CA2869945 a composition, method, or use patent?
It is titled as a medical-use patent (“Use of indomethacin…”), but the exact claim type must be verified from the claim set.
-
Does CA2869945 cover indomethacin as a drug substance?
A substance claim cannot be concluded from the title alone; substance coverage depends on whether independent claims are drafted as composition/product claims versus use claims.
-
What closest prior art categories usually challenge indomethacin use patents in Canada?
Earlier indication-specific indomethacin use filings, indomethacin combination therapy patents, and known dosing/route use disclosures.
-
Will CA2869945 be enforceable against generic entry in Canada?
Enforceability risk depends on whether it is listed on the NOC/c Patent Register for the relevant drug product and on litigation status.
-
What matters most for freedom-to-operate around CA2869945?
The medical-use claim boundaries (indication, patient qualifiers, route/dose timing, and combinations) and whether prior Canadian filings predate its priority.
References
[1] Canadian Intellectual Property Office (CIPO). Patent publication CA2869945 (title: “Use of indomethacin…”).
